Evidence map›Paper›PMID 39190826›Full record

Trial reportOcular immunology and inflammation2025

Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease.

Miel Sundararajan, Sivakumar R Rathinam, Radhika Thundikandy, Anuradha Kanakath, S Balamurugan, R Vedhanayaki, D Claire Miller, Lyndell L Lim, Eric B Suhler, Hassan A Al-Dhibi and 8 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ocular immunology and inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Miel SundararajanDepartment of Ophthalmology, University of Washington, Seattle, Washington, USA.
Sivakumar R RathinamUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Radhika ThundikandyUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India.
Anuradha KanakathUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India.
S BalamuruganUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India.
R VedhanayakiUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
D Claire MillerFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.
Lyndell L LimCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Eric B SuhlerCasey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA.
Hassan A Al-DhibiDivision of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
Lourdes Arellanes-GarciaInflammatory Eye Disease Clinic, Asociación Para Evita la Ceguera en México, México City, México.
Amit K ReddyFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.
Shu FengDepartment of Ophthalmology, University of Washington, Seattle, Washington, USA.
Thuy DoanFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.
Travis C PorcoFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.
Jessica G ShanthaFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.
Nisha R AcharyaFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.
John A GonzalesFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-0558-9793

Funding

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis TrialU10EY021125 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ACHARYA, NISHA · 2012 to 2016
$4.6M
NEI NIH HHS U10 EY021125
6 · The paper itself

Abstract

purposeThe choroidal thickening and serous retinal detachments that characterize Vogt-Koyanagi-Harada (VKH) disease can be imaged in detail using spectral domain optical coherence tomography (SD-OCT). Whether specific qualitative and quantitative SD-OCT features at presentation were associated with visual outcomes in a randomized controlled trial comparing methotrexate to mycophenolate for steroid-sparing control of uveitis were evaluated.

methodsAn exploratory subanalysis of data from the FAST trial in which SD-OCT images from VKH participants were analyzed for presence/absence of bacillary detachments, retinal pigment epithelium (RPE) folds, and internal limiting membrane (ILM) fluctuations was performed. A modified RPE undulation index was calculated to provide a quantifiable surrogate marker for choroidal folds.

resultsSD-OCT images were available from 158 eyes with VKH. At baseline, bacillary detachments were present in 23.5% of eyes, RPE folds in 22.8% of eyes, and ILM fluctuations in 35.2% of eyes. For each 0.1 unit increase in modified RPE undulation index, there was an associated 0.13 increase in mean logMAR BSCVA at baseline. None of the SD-OCT features were associated with BSCVA at the 6-month primary endpoint. Indeed, mean final BSCVA was similar in those with and without the SD-OCT features of interest at baseline, and was between 0.1 and 0.2 logMAR (Snellen visual acuity 20/25 to 20/30).

conclusionsWhile eyes with VKH may present with a variety of SD-OCT imaging pathology prior to starting immunosuppression with methotrexate or mycophenolate mofetil, final visual outcome in our study was excellent. With appropriate immunosuppression, good visual outcomes are possible in VKH.ClinicalTrials.gov Identifier NCT01829295Date of Registration: April 11, 2013.

Indexed as

Macula LuteaTomography, Optical CoherenceUveomeningoencephalitic SyndromeVisual AcuityAdultFemaleFluorescein AngiographyFollow-Up StudiesHumansImmunosuppressive AgentsMaleMethotrexateMiddle AgedMycophenolic AcidRetinal DetachmentRetinal Pigment EpitheliumImmunosuppressive AgentsMethotrexateMycophenolic AcidRetinal pigment epithelium undulation indexSD-OCTVogt-Koyanagi-Harada

Identifiers

PMID39190826
PMCPMC11785501

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.